Papillary renal cell carcinoma (pRCC) is the second most common type of kidney cancer, but it is rare and very little is known about the biology of pRCC. However, a subset of patients with pRCC have an alteration (mutation) in the MET gene, which may be helpful in furthering the understanding of the disease.
The findings from a phase 2 clinical trial were presented at the American Society for Clinical Oncology (ASCO) 2017 Genitourinary (GU) Cancers Symposium in Orlando, Florida last month. In this single-arm, biomarker-based study, patients with advanced pRCC were given savolitinib, a selective MET inhibitor. Savolitinib was generally well tolerated in patients with an alteration to the MET gene; however, further clinical investigation is needed.